Form 4: Fennec Pharmaceuticals CFO Robert Andrade Sells Shares Under 10b5-1 Plan

Robert Andrade, CFO of Fennec Pharmaceuticals, sold 13,975 common shares at a price of $10.9013 per share on March 26, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 26, 2024, Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, sold 13,975 common shares of the company.
• The sale was executed at a price of $10.9013 per share.
• The transaction was conducted under a pre-existing 10b5-1 trading plan adopted on August 16, 2023.
• Following the transaction, Andrade directly owns 91,771 common shares of Fennec Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider share sale under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• It is common for executives at pharmaceutical companies to have 10b5-1 trading plans in place.
• These plans are often used to diversify personal holdings or to meet liquidity needs.
• The volume of shares sold is relatively small compared to the total outstanding shares of Fennec Pharmaceuticals, suggesting it is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates